Skip to main content
Clinical Trials/ISRCTN98159689
ISRCTN98159689Completed未知

A randomised controlled trial of TRANSrectal biopsy versus Local Anaesthetic Transperineal biopsy Evaluation (TRANSLATE) of potentially clinically significant prostate cancer (the TRANSLATE trial)

niversity of Oxford0 sites1,042 target enrollmentStarted: January 28, 2021Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
1,042

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Sex
Male

Inclusion Criteria

  • All biopsy-naïve men who (regardless of age), during an investigation for suspicion of possible PCa, require a prostate biopsy and who have had one or more of the below findings:
  • 1. A PSA value above the age-adjusted upper limit of normal, regardless of the MRI result
  • 2. An abnormal pre-biopsy MRI
  • 3. An abnormal prostate DRE (regardless of serum PSA or MRI result)
  • 4. Considered suitable to tolerate a LATP biopsy procedure

Exclusion Criteria

  • 1. Had a previous prostate biopsy
  • 2. Dysuria on the day of biopsy or untreated urinary tract infection (UTI)
  • 3. Immunocompromised (due to history of prior immunocompromising medical condition, or medications e.g. steroids or methotrexate)
  • 4. May need enhanced antibiotic prophylaxis (e.g. due to indwelling catheter or recurrent UTIs)
  • 5. Previous abdominoperineal resection (i.e. absent rectum)
  • 6. Unable to recline adequately in Lloyd-Davis / lithotomy position (e.g. hip surgery or contractures)
  • 7. Unable to have a pre-biopsy MRI (e.g. pacemaker, eGFR <50, or claustrophobia)
  • 8. PSA >50 ng/ml (i.e. locally advanced/metastatic PCa easily detectable by TRUS)

Investigators

Similar Trials

A study that aims to find out in the NHS... | Clinical Trial